IN8bio, Inc. INAB

IN8bio reported second quarter 2026 financial results and recent business highlights. Quarterly results and business updates deliver moderate information that may shift near-term investor views without major strategic shifts.

IN8bio announced publication in The Journal of Clinical Oncology showing its DeltEx DRI therapy doubles progression-free survival in newly diagnosed glioblastoma patients. Positive phase 1 data publication for lead candidate in glioblastoma signals strong efficacy that can drive valuation gains and accelerate development.

IN8bio published research in Nature Communications on gamma-delta T cell engineering advances and combination therapies. Prestigious journal publication on core T cell platform may lift research credibility and sentiment but lacks clinical or financial milestones.

IN8bio presented updated data showing overall survival surpassing 19.5 months for DeltEx DRI in newly diagnosed glioblastoma patients at ASCO 2026. Positive clinical survival data for IN8bio's lead glioblastoma candidate signals major advancement in development and investor outlook.

IN8bio presented new translational data demonstrating DeltEx DRI reshapes the immune landscape in glioblastoma. Positive translational data on DeltEx DRI for glioblastoma advances IN8bio's immunotherapy pipeline and could significantly boost investor sentiment.

IN8bio, Inc. presented preclinical data on INB-619, a T Cell Engager (TCE) targeting autoimmune diseases, at the ASGCT 2025 conference. The data highlights the potential of INB-619 to modulate immune responses, offering a promising therapeutic avenue for conditions like multiple sclerosis and rheumatoid arthritis. The findings suggest that INB-619 could enhance T cell activity while reducing harmful autoimmunity, positioning IN8bio as a key player in the autoimmune treatment landscape. The presentation of promising preclinical data for INB-619 could significantly influence investor sentiment and the company's strategic direction in the autoimmune disease market.

IN8bio, Inc. reported strong Phase 1 clinical data for INB-100, showing 100% relapse-free survival in AML patients after 20.1 months. The company celebrated the 5th anniversary of its first gamma-delta T cell therapy patient in remission. New data on the INB-600 T cell engager platform was presented at the AACR 2025 Annual Meeting, highlighting its potential in oncology and autoimmune diseases. IN8bio raised approximately $4.1 million in Q1 2025 and continues to focus on key milestones, including upcoming presentations at ASCO and ISCT meetings. Financially, R&D expenses decreased to $3.0 million, and the net loss narrowed to $5.6 million, with cash reserves at $11.9 million as of March 31, 2025. The reported clinical successes and new data presentations indicate significant advancements in IN8bio's product pipeline, likely influencing future market performance.

IN8bio, Inc. (INAB) reported first quarter 2026 financial results and recent business highlights. Quarterly financial results and business highlights for a clinical-stage biotech can moderately influence investor sentiment and stock trajectory.

IN8bio, Inc. (INAB) will showcase its next-generation T Cell Engager platform and new clinical data at an upcoming R&D Day and medical conferences. Showcasing next-generation T Cell Engager platform alongside new clinical data signals major strategic advancements poised to significantly enhance competitive positioning and investor sentiment.

IN8bio reported fourth quarter and full-year 2025 financial results, highlighting durable survival improvements in glioblastoma trials, advancing pipeline programs, and a strengthened financial position providing runway into 2026. Durable glioblastoma survival data combined with pipeline advances and extended cash runway position INAB for significant clinical progress and positive investor sentiment.

IN8bio, Inc. has promoted Kate Rochlin, Ph.D., to the position of President and Chief Operating Officer. This strategic move is expected to enhance the company's operational capabilities and leadership as it continues to advance its innovative therapies in the field of cancer treatment. Leadership changes can moderately influence operational effectiveness and strategic direction.

IN8bio, Inc. (INAB) announced its participation in several upcoming investor and scientific conferences in February. The company aims to showcase its advancements and engage with stakeholders in the biotechnology sector, highlighting its commitment to innovation and collaboration. Participation in conferences can enhance visibility and networking opportunities, potentially influencing market sentiment and investor interest.

IN8bio, Inc. presented updated Phase I/II clinical trial data showing significant and durable survival improvements in patients with newly diagnosed glioblastoma. The results indicate a promising potential for IN8bio's treatment approach, which may enhance patient outcomes in this challenging cancer type. The data highlights the company's commitment to advancing innovative therapies in oncology. The presentation of meaningful survival data could significantly influence investor sentiment and the company's future trajectory in the oncology market.

IN8bio, Inc. has announced the pricing of a private placement of up to $40.2 million. The funds will be used to advance the company's novel gamma-delta T cell engager technology, which is aimed at improving cancer treatment. This financing is expected to support ongoing clinical trials and further development of IN8bio's innovative therapies. The private placement is a significant financial move that will enable the advancement of critical cancer therapies, potentially altering the company's trajectory.

IN8bio, Inc. (INAB) reported its financial results for the third quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its innovative therapies and maintain a strong pipeline, reflecting its commitment to addressing unmet medical needs. Recent achievements include progress in clinical trials and strategic partnerships aimed at enhancing its market position. Overall, the report underscores IN8bio's ongoing efforts to drive growth and deliver value to stakeholders. Significant advancements in clinical trials and strategic partnerships are likely to impact future performance and investor sentiment.

IN8bio, Inc. has expanded its Phase 1 clinical trial for INB-100 by adding The Ohio State University as a new site. This expansion aims to enhance the trial's reach and patient enrollment, potentially accelerating the development of INB-100, a treatment for glioblastoma. The addition of a prominent institution like Ohio State is expected to strengthen the trial's credibility and increase collaboration opportunities. The addition of a major research institution is likely to significantly enhance the trial's scope and credibility, impacting future development and investor sentiment.

IN8bio, Inc. presented data on its T cell engager technology, highlighting its ability to achieve deep B cell depletion for autoimmune indications. This advancement could potentially enhance treatment options for patients with autoimmune diseases, showcasing the company's innovative approach in the biopharmaceutical sector. The presentation of significant data on T cell engagers indicates a major strategic move that could influence IN8bio's market positioning and investor sentiment.

IN8bio, Inc. (INAB) reported its financial results for the second quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its clinical programs and strengthen its financial position, reflecting progress in its strategic initiatives. Recent achievements include advancements in product development and collaborations aimed at enhancing its market presence. Significant advancements in clinical programs and strategic initiatives are likely to impact future performance and investor sentiment.

IN8bio, Inc. announced that a patient treated with INB-200 in their glioblastoma trial has achieved four years in remission. This milestone highlights the potential effectiveness of INB-200 as a treatment option for glioblastoma, a notoriously aggressive brain cancer. The company continues to focus on advancing its innovative therapies in the field of immuno-oncology. The achievement of a patient reaching four years in remission could significantly enhance investor sentiment and validate the therapeutic potential of INB-200.

IN8bio, Inc. announced positive Phase 1 trial results for INB-200 in newly diagnosed glioblastoma multiforme (GBM), showing a median progression-free survival (mPFS) of 16.1 months, significantly exceeding the standard-of-care (SOC) mPFS of 6.9 months. The treatment was well-tolerated with no serious toxicities reported. Notably, four patients remain alive and progression-free for over two years. The data were presented at the 2025 ASCO Annual Meeting, highlighting the potential of INB-200 to improve outcomes for GBM patients, including those with chemotherapy-resistant tumors. A conference call with the principal investigator is scheduled for today to discuss the findings further. The significant improvement in mPFS and the potential to redefine treatment for GBM patients indicate a major strategic advancement for IN8bio.

IN8bio, Inc. presented data at ISCT 2025 showcasing its proprietary γδ T cell manufacturing process, which consistently generates robust clinical products. The findings highlight the potential of this technology in advancing cell therapy applications. The presentation of consistent and robust clinical products could significantly enhance IN8bio's competitive positioning and investor sentiment.

IN8bio, Inc. (Nasdaq: INAB) announced it will present new clinical and preclinical data from its gamma-delta T cell therapies at several upcoming scientific conferences, including AACR, ISCT, ASGCT, and ASCO. CEO William Ho emphasized the scientific rigor and clinical potential of their gamma-delta T cell platform, highlighting programs like INB-200/400 for glioblastoma and novel T cell engager technologies. Presentations will cover topics such as manufacturing processes and the molecular signatures of expanded gamma-delta T cell products. The upcoming presentations at major scientific conferences could significantly enhance IN8bio's visibility and credibility in the oncology field, potentially impacting investor sentiment and future market performance.

IN8bio, Inc. presented new data from its next-generation Gamma-Delta T Cell Engager (TCE) platform at the AACR 2025 conference, showcasing promising results that could enhance cancer treatment options. The data highlights the platform's potential in targeting tumors more effectively, which may lead to improved patient outcomes and expanded therapeutic applications. The new data from the TCE platform could significantly enhance IN8bio's competitive position and market potential in cancer therapies.

IN8bio, Inc. announced a poster presentation at the AACR Annual Meeting 2025, showcasing its novel gamma-delta T cell engager platform for cancer immunotherapy. The platform aims to leverage the unique properties of gamma-delta T cells to enhance immune responses against various cancers, including acute myeloid leukemia and B-ALL. CEO William Ho emphasized the potential of this technology to address limitations of current therapies. The presentation is scheduled for April 30, 2025. The introduction of a novel gamma-delta T cell engager platform could significantly enhance IN8bio's competitive positioning and market potential in cancer immunotherapy.

IN8bio, Inc. will participate in the 11th Annual Immuno-Oncology 360° Conference in 2025, showcasing its advancements in immunotherapy and engaging with industry leaders and stakeholders in the field. Participation in a prominent conference may enhance visibility and networking opportunities, potentially influencing future collaborations and market sentiment.

IN8bio, Inc. (NASDAQ:INAB) announced its new γδ T cell engager platform, INB-600, and reported 2024 financial results, showing no revenues and a net loss of $30.4 million. All acute myeloid leukemia (AML) patients in trials remain in complete remission. Research and development expenses rose slightly to $17.0 million, while general and administrative expenses decreased to $12.6 million. Cash and marketable securities totaled $11.1 million at year-end, down from $21.3 million in 2023. The company raised $11.6 million through a private placement and anticipates sufficient cash to support operations until March 2026. INB-600 aims to target CD19 and may offer advantages over existing therapies, including reduced risk of cytokine release syndrome. The introduction of the INB-600 platform and positive trial results for AML patients indicate significant potential for future growth and market impact.

IN8bio, Inc. reported its fourth quarter and full-year 2024 financial results, highlighting ongoing clinical programs showing durable remissions in glioblastoma and acute myeloid leukemia (AML). The company introduced its INB-600 platform, targeting CD19 for oncology and autoimmune diseases, and reported 100% relapse-free survival in treated AML patients. Financially, R&D expenses increased slightly, while G&A expenses decreased, leading to a net loss of $30.7 million for the year. The company raised approximately $16.6 million to extend its cash runway into March 2026. Upcoming milestones include accelerating patient enrollment for INB-100 and advancing preparations for a potential Phase 2 trial. Significant advancements in clinical programs and the introduction of a novel platform could alter the company's trajectory and investor sentiment.

IN8bio, Inc. has announced the launch of its advanced Gamma-Delta (γδ) T cell Engager (TCE) platform, aimed at treating oncology and autoimmune diseases. This innovative platform is designed to enhance the efficacy of T cell therapies, potentially offering new treatment options for patients with various cancers and autoimmune conditions. The company aims to leverage this technology to improve patient outcomes and expand its therapeutic portfolio. The introduction of a new T cell Engager platform could significantly enhance IN8bio's product offerings and competitive positioning in the oncology and autoimmune disease markets.

IN8bio, Inc. (INAB) announced its participation in the TD Cowen 45th Annual Health Care Conference, where the company will present its latest developments and strategic initiatives. This event provides a platform for IN8bio to engage with investors and industry stakeholders, highlighting its advancements in cell therapy and potential market opportunities. Participation in a significant healthcare conference can enhance investor engagement and market visibility, potentially influencing the company's trajectory.

IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, at 11:00 a.m. ET. The presentation will be available via a live webcast. IN8bio is focused on developing gamma-delta T cell therapies for cancer, with its lead program INB-400 currently in a Phase 2 trial for glioblastoma (GBM) and additional programs in Phase 1 trials for various tumors. The presentation at a significant conference may enhance investor interest and awareness of IN8bio's ongoing clinical programs.